Berliner Boersenzeitung - Painkiller sale plan to US gives France major headache

EUR -
AED 4.268743
AFN 80.737785
ALL 98.068775
AMD 449.244098
ANG 2.079957
AOA 1065.72103
ARS 1464.413018
AUD 1.780672
AWG 2.091929
AZN 1.978824
BAM 1.958172
BBD 2.361605
BDT 142.132142
BGN 1.956907
BHD 0.438174
BIF 3485.491432
BMD 1.162183
BND 1.498702
BOB 8.083721
BRL 6.458253
BSD 1.169817
BTN 100.361552
BWP 15.730051
BYN 3.828337
BYR 22778.77832
BZD 2.349392
CAD 1.593695
CDF 3354.059249
CHF 0.931176
CLF 0.029296
CLP 1124.22557
CNY 8.336364
CNH 8.347644
COP 4689.98775
CRC 590.014591
CUC 1.162183
CUP 30.797838
CVE 110.397757
CZK 24.668447
DJF 208.312296
DKK 7.462769
DOP 70.575477
DZD 151.311537
EGP 57.423092
ERN 17.432739
ETB 162.519034
FJD 2.649192
FKP 0.865082
GBP 0.866907
GEL 3.149797
GGP 0.865082
GHS 12.16563
GIP 0.865082
GMD 83.093957
GNF 10148.291015
GTQ 8.977873
GYD 244.644194
HKD 9.123069
HNL 30.601062
HRK 7.531406
HTG 153.592057
HUF 400.282987
IDR 18929.048565
ILS 3.915236
IMP 0.865082
INR 99.708757
IQD 1532.456021
IRR 48956.940711
ISK 142.447962
JEP 0.865082
JMD 186.946419
JOD 0.823912
JPY 172.968211
KES 151.141606
KGS 101.628918
KHR 4687.556291
KMF 493.491733
KPW 1045.991755
KRW 1610.772885
KWD 0.355325
KYD 0.974881
KZT 615.245149
LAK 25218.54322
LBP 104114.982593
LKR 352.19656
LRD 234.544066
LSL 20.820216
LTL 3.431623
LVL 0.702993
LYD 6.339678
MAD 10.545581
MDL 19.769944
MGA 5186.28132
MKD 61.634117
MMK 2440.214556
MNT 4166.247054
MOP 9.458756
MRU 46.487763
MUR 53.054232
MVR 17.900509
MWK 2028.456748
MXN 21.839101
MYR 4.938697
MZN 74.332521
NAD 20.820216
NGN 1777.627801
NIO 43.052142
NOK 11.899744
NPR 160.578483
NZD 1.953018
OMR 0.446856
PAB 1.169807
PEN 4.171252
PGK 4.838861
PHP 66.211909
PKR 332.926321
PLN 4.258885
PYG 9057.970482
QAR 4.264628
RON 5.077108
RSD 117.132893
RUB 90.6518
RWF 1690.347249
SAR 4.358862
SBD 9.668847
SCR 17.0619
SDG 697.891827
SEK 11.2837
SGD 1.492829
SHP 0.913293
SLE 26.090529
SLL 24370.391933
SOS 668.50966
SRD 43.540593
STD 24054.832706
SVC 10.235397
SYP 15110.523652
SZL 20.813208
THB 37.71296
TJS 11.183248
TMT 4.079261
TND 3.373232
TOP 2.72195
TRY 46.778121
TTD 7.941618
TWD 34.107762
TZS 3039.107052
UAH 48.918748
UGX 4193.042288
USD 1.162183
UYU 47.677334
UZS 14855.992707
VES 135.771968
VND 30402.695961
VUV 138.884486
WST 3.189282
XAF 656.75242
XAG 0.030696
XAU 0.000348
XCD 3.140857
XDR 0.816789
XOF 656.75242
XPF 119.331742
YER 280.492372
ZAR 20.794206
ZMK 10461.039735
ZMW 26.696313
ZWL 374.222313
  • CMSC

    0.0900

    22.314

    +0.4%

  • CMSD

    0.0250

    22.285

    +0.11%

  • RBGPF

    0.0000

    69.04

    0%

  • SCS

    0.0400

    10.74

    +0.37%

  • RELX

    0.0300

    53

    +0.06%

  • RIO

    -0.1400

    59.33

    -0.24%

  • GSK

    0.1300

    41.45

    +0.31%

  • NGG

    0.2700

    71.48

    +0.38%

  • BP

    0.1750

    30.4

    +0.58%

  • BTI

    0.7150

    48.215

    +1.48%

  • BCC

    0.7900

    91.02

    +0.87%

  • JRI

    0.0200

    13.13

    +0.15%

  • VOD

    0.0100

    9.85

    +0.1%

  • BCE

    -0.0600

    22.445

    -0.27%

  • RYCEF

    0.1000

    12

    +0.83%

  • AZN

    -0.1200

    73.71

    -0.16%

Painkiller sale plan to US gives France major headache
Painkiller sale plan to US gives France major headache / Photo: Valentine CHAPUIS - AFP

Painkiller sale plan to US gives France major headache

The planned sale of France's best-selling medical drug to US investors has caused the government a splitting headache after an outcry against the project from politicians on all sides.

Text size:

Even President Emmanuel Macron is involved in the debate centred on a perceived "loss of sovereignty" if popular painkiller Doliprane falls into American hands.

Doliprane is the brand under which healthcare giant Sanofi sells paracetamol, a non-opioid analgesic for the alleviation of mild to moderate pain, and of fever.

In French pharmacies, the brand's colourful boxes often line entire shelf walls, and Doliprane comes in many doses -- from 100 mg for newborn babies to 1,000 mg for adults -- and in tablet, capsule, suppository and liquid forms.

It is so ubiquitous that French people call any paracetamol product Doliprane, even when it is made by a different manufacturer.

Sanofi, which is France's biggest healthcare company and among the world's top 12, has found out over the past few days just how attached the French are to the drug.

Political and trade union reactions came in hard and fast after the company announced last week that it was in talks with New York-based private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50-percent controlling stake in its subsidiary Opella, which makes Doliprane along with other consumer healthcare products.

The planned spinoff, it said, would be part of Sanofi's strategy to focus less on over-the-counter medication and more on innovative medicines and vaccines, including for polio, the flu and meningitis.

"This is another symbol for the loss of our sovereignty," thundered Fabien Roussel, France's Communist party leader, calling the planned sale "shameful".

At the other end of the political spectrum Jordan Bardella, president of the farright RN party, said that "the piecemeal sale of France carries on".

- 'Protect France' -

Green party deputy Marine Tondelier said the government had "learned nothing" from the Covid pandemic when France suffered from medication bottlenecks blamed mostly on the outsourcing of production to foreign countries.

An adhoc group of centre-right lawmakers -- including from Macron's party -- meanwhile stated that the sale represented "a very worrying risk for our national security".

Boris Vallaud, parliamentary leader for the Socialists, reminded the government of 2022 when a sharp rise in demand for paracetamol caused some shortages in French pharmacies.

"Already some months ago, paracetamol was nowhere to be found," he said. "And now they want to give it up completely?"

In a message to Finance Minister Antoine Armand -- in the job only since last month -- the group of deputies said the planned sale went against "the re-establishment of France's sovereignty in the health sector".

The government had the legal option, they said, of posing conditions or blocking the sale on the grounds that it concerns a "sensitive" industry.

Macron himself entered the fray Monday, saying that "the government has the instruments needed to protect France" from any unwanted "capital ownership".

The American investment fund is offering more than 15 billion euros ($16.4 billion) for Opella, according to Les Echos, a French business daily.

Faced with the protests, Armand on Friday told Sanofi and the potential buyer that Opella's "headquarters and decision-making centres" had to remain in France.

On Monday, Industry Minister Marc Ferracci said that current production also had to stay, "to safeguard employment and to secure supply for French people".

The same went for research and development facilities, he said.

Speaking to broadcaster France 3, Ferracci said the government would invoke a procedure for the control of foreign investment if the buyers failed to meet the demands.

But he added: "I honestly believe that those commitments will be made."

burs-jh/as/rl

(G.Gruner--BBZ)